Merck & Co., Inc. (MRK) Average EV/Assets Ratio
The current ev/assets ratio for Merck & Co., Inc. (MRK) is 2.64x as of Tuesday, June 9, 2026, shown against its trailing averages.
Average EV/Assets Ratio Chart
MRK EV/Assets Ratio Averages
EV/ASSETS RATIO CURRENT
2.64x
EV/ASSETS RATIO TTM
2.21x
EV/ASSETS RATIO 3Y
2.57x
EV/ASSETS RATIO 5Y
2.53x
EV/ASSETS RATIO 10Y
2.39x
EV/ASSETS RATIO 15Y
2.07x
EV/ASSETS RATIO 20Y
1.94x
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis